. 2018 Jun 29;36(2):103–113. doi: 10.3857/roj.2018.00045

Table 2.

Univariate and multivariate analysis of survival rates

Variable	OS						PFS
	Univariate			Multivariate			Univariate			Multivariate
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (≥65 yr)	1.44	0.69–3.01	0.328				1.38	0.68–2.80	0.370
Sex (female)	0.96	0.49–1.89	0.896				0.78	0.40–1.52	0.466
ECOG PS (≥2)	1.42	0.70–2.87	0.327				1.67	0.85–3.30	0.132
Stage (IVA vs. others)	0.10	0.01–0.76	0.026^*	0.04	0.00–0.36	0.004^*	0.26	0.08–0.88	0.021^*	0.14	0.04-0.55	0.005^*
Surgery	0.32	0.16–0.64	0.001^*	0.27	0.13–0.58	0.001^*	0.42	0.22–0.81	0.007^*	0.47	0.24-0.91	0.026^*
IMRT	0.61	0.29–1.25	0.173	0.30	0.13–0.69	0.005^*	0.51	0.26–1.01	0.049^*	0.33	0.15-0.72	0.005^*
Chemotherapy	0.62	0.28–1.37	0.235				0.91	0.41–2.02	0.809
EQD2₁₀ dose (≥62 Gy)	0.87	0.42–1.83	0.719				1.08	0.52–2.24	0.836

OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; IMRT, intensity-modulated radiotherapy.

p < 0.05.